{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:12:55Z","timestamp":1788358375299,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81602330"],"award-info":[{"award-number":["81602330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Province Natural Science Foundation of China","award":["ZR2021MH024"],"award-info":[{"award-number":["ZR2021MH024"]}]},{"name":"Shandong Province Natural Science Foundation of China","award":["ZR2023MC181"],"award-info":[{"award-number":["ZR2023MC181"]}]},{"name":"Shandong Province Key Research and Development Plan","award":["2019GSF108195"],"award-info":[{"award-number":["2019GSF108195"]}]},{"name":"Zibo Municipal Medical and Health Technology Project","award":["20240309032"],"award-info":[{"award-number":["20240309032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12678-x","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:16:58Z","timestamp":1788355018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein-protein interactions as therapeutic targets in breast cancer: integrated computational and experimental advances, mechanisms and clinical translation"],"prefix":"10.1007","volume":"53","author":[{"given":"Kui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"4","key":"12678_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, Mccormack V, Sung H, Houssami N, Morgan E et al (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31(4):1154\u20131162. https:\/\/doi.org\/10.1038\/s41591-025-03502-3","journal-title":"Nat Med"},{"key":"12678_CR2","doi-asserted-by":"publisher","unstructured":"Dustin D Gu GFuqua SaW,(2019) ESR1 mutations in breast cancer. Cancer 125(21):3714\u20133728. https:\/\/doi.org\/10.1002\/cncr.32345","DOI":"10.1002\/cncr.32345"},{"issue":"2","key":"12678_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S et al (2020) The 2019 World Health Organization classification of tumours of the breast. Histopathology 77(2):181\u2013185. https:\/\/doi.org\/10.1111\/his.14091","journal-title":"Histopathology"},{"issue":"7418","key":"12678_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"1","key":"12678_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1172\/JCI33154","volume":"118","author":"DM Brantley-Sieders","year":"2008","unstructured":"Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM et al (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118(1):64\u201378. https:\/\/doi.org\/10.1172\/JCI33154","journal-title":"J Clin Invest"},{"issue":"1","key":"12678_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q et al (2023) Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16(1):100. https:\/\/doi.org\/10.1186\/s13045-023-01497-3","journal-title":"J Hematol Oncol"},{"key":"12678_CR7","doi-asserted-by":"publisher","unstructured":"Veneziano M, Savini I, Cortellesi E, Gasperi V, Gambacurta ACatani MV (2025) Bioinformatics Strategies in Breast Cancer Research. Biomolecules 15(10). https:\/\/doi.org\/10.3390\/biom15101409","DOI":"10.3390\/biom15101409"},{"issue":"3","key":"12678_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41568-024-00784-6","volume":"25","author":"H Fu","year":"2025","unstructured":"Fu H, Mo XIvanov AA (2025) Decoding the functional impact of the cancer genome through protein-protein interactions. Nat Rev Cancer 25(3):189\u2013208. https:\/\/doi.org\/10.1038\/s41568-024-00784-6","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"12678_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccr.2013.03.021","volume":"23","author":"Y Hao","year":"2013","unstructured":"Hao Y, Wang C, Cao B, Hirsch BM, Song J, Markowitz SD et al (2013) Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 23(5):583\u2013593. https:\/\/doi.org\/10.1016\/j.ccr.2013.03.021","journal-title":"Cancer Cell"},{"issue":"5","key":"12678_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.chembiol.2020.11.010","volume":"28","author":"C Tang","year":"2021","unstructured":"Tang C, Mo X, Niu Q, Wahafu A, Yang X, Qui M et al (2021) Hypomorph mutation-directed small-molecule protein-protein interaction inducers to restore mutant SMAD4-suppressed TGF-beta signaling. Cell Chem Biol 28(5):636\u2013647e635. https:\/\/doi.org\/10.1016\/j.chembiol.2020.11.010","journal-title":"Cell Chem Biol"},{"issue":"10","key":"12678_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41389-021-00355-6","volume":"10","author":"K Xu","year":"2021","unstructured":"Xu K, Wang R, Xie H, Hu L, Wang C, Xu J et al (2021) Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. Oncogenesis 10(10):66. https:\/\/doi.org\/10.1038\/s41389-021-00355-6","journal-title":"Oncogenesis"},{"key":"12678_CR12","doi-asserted-by":"publisher","first-page":"104389","DOI":"10.1016\/j.critrevonc.2024.104389","volume":"199","author":"OH Rodriguez-Bejarano","year":"2024","unstructured":"Rodriguez-Bejarano OH, Parra-Lopez CPatarroyo MA (2024) A review concerning the breast cancer-related tumour microenvironment. Crit Rev Oncol Hematol 199:104389. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104389","journal-title":"Crit Rev Oncol Hematol"},{"key":"12678_CR13","doi-asserted-by":"publisher","first-page":"14356","DOI":"10.1038\/ncomms14356","volume":"8","author":"Z Li","year":"2017","unstructured":"Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S et al (2017) The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nat Commun 8:14356. https:\/\/doi.org\/10.1038\/ncomms14356","journal-title":"Nat Commun"},{"issue":"6","key":"12678_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1267\/ahc.21-00084","volume":"54","author":"E Iwabuchi","year":"2021","unstructured":"Iwabuchi E, Miki YSasano H (2021) The Visualization of Protein-Protein Interactions in Breast Cancer: Deployment Study in Pathological Examination. Acta Histochem Cytochem 54(6):177\u2013183. https:\/\/doi.org\/10.1267\/ahc.21-00084","journal-title":"Acta Histochem Cytochem"},{"issue":"1","key":"12678_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/imr.12244","volume":"263","author":"J Cierpicki TGrembecka","year":"2015","unstructured":"Cierpicki TGrembecka J (2015) Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev 263(1):279\u2013301. https:\/\/doi.org\/10.1111\/imr.12244","journal-title":"Immunol Rev"},{"issue":"6563","key":"12678_CR16","doi-asserted-by":"publisher","first-page":"eabf3066","DOI":"10.1126\/science.abf3066","volume":"374","author":"M Kim","year":"2021","unstructured":"Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M et al (2021) A protein interaction landscape of breast cancer. Science 374(6563):eabf3066. https:\/\/doi.org\/10.1126\/science.abf3066","journal-title":"Science"},{"issue":"1","key":"12678_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41467-023-35789-6","volume":"14","author":"ML Jenkins","year":"2023","unstructured":"Jenkins ML, Ranga-Prasad H, Parson MH, Harris NJ, Rathinaswamy MKBurke JE (2023) Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. Nat Commun 14(1):181. https:\/\/doi.org\/10.1038\/s41467-023-35789-6","journal-title":"Nat Commun"},{"issue":"3","key":"12678_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.21873\/anticanres.16241","volume":"43","author":"A Voutsadakis IAStravodimou","year":"2023","unstructured":"Voutsadakis IAStravodimou A (2023) Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. Anticancer Res 43(3):967\u2013981. https:\/\/doi.org\/10.21873\/anticanres.16241","journal-title":"Anticancer Res"},{"issue":"6","key":"12678_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","volume":"22","author":"B Xia","year":"2006","unstructured":"Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719\u2013729. https:\/\/doi.org\/10.1016\/j.molcel.2006.05.022","journal-title":"Mol Cell"},{"issue":"1","key":"12678_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"G Kim MPLozano","year":"2018","unstructured":"Kim MPLozano G (2018) Mutant p53 partners in crime. Cell Death Differ 25(1):161\u2013168. https:\/\/doi.org\/10.1038\/cdd.2017.185","journal-title":"Cell Death Differ"},{"issue":"21","key":"12678_CR21","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1074\/jbc.M201405200","volume":"277","author":"S Strano","year":"2002","unstructured":"Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277(21):18817\u201318826. https:\/\/doi.org\/10.1074\/jbc.M201405200","journal-title":"J Biol Chem"},{"issue":"3","key":"12678_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ccr.2009.11.025","volume":"17","author":"P Stambolsky","year":"2010","unstructured":"Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z et al (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17(3):273\u2013285. https:\/\/doi.org\/10.1016\/j.ccr.2009.11.025","journal-title":"Cancer Cell"},{"issue":"4","key":"12678_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T et al (2021) Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39(4):494\u2013508e495. https:\/\/doi.org\/10.1016\/j.ccell.2021.01.003","journal-title":"Cancer Cell"},{"issue":"19","key":"12678_CR24","doi-asserted-by":"publisher","first-page":"E3766","DOI":"10.1073\/pnas.1619832114","volume":"114","author":"K Liu","year":"2017","unstructured":"Liu K, Lin FT, Graves JD, Lee YJLin WC (2017) Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. Proc Natl Acad Sci U S A 114(19):E3766\u2013E3775. https:\/\/doi.org\/10.1073\/pnas.1619832114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"12678_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.21873\/cgp.20379","volume":"20","author":"GM Adinew","year":"2023","unstructured":"Adinew GM, Messeha S, Taka E, Ahmed SASoliman KFA (2023) The Role of Apoptotic Genes and Protein-Protein Interactions in Triple-negative Breast Cancer. Cancer Genomics Proteom 20(3):247\u2013272. https:\/\/doi.org\/10.21873\/cgp.20379","journal-title":"Cancer Genomics Proteom"},{"key":"12678_CR26","doi-asserted-by":"publisher","unstructured":"Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ et al (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife 5. https:\/\/doi.org\/10.7554\/eLife.12792","DOI":"10.7554\/eLife.12792"},{"key":"12678_CR27","doi-asserted-by":"publisher","unstructured":"Khatpe AS, Adebayo AK, Herodotou CA, Kumar BNakshatri H (2021) Nexus between PI3K\/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel) 13(3). https:\/\/doi.org\/10.3390\/cancers13030369","DOI":"10.3390\/cancers13030369"},{"issue":"3\u20134","key":"12678_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10911-012-9265-1","volume":"17","author":"S Wang","year":"2012","unstructured":"Wang S, Bai L, Lu J, Liu L, Yang CYSun H (2012) Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia 17(3\u20134):217\u2013228. https:\/\/doi.org\/10.1007\/s10911-012-9265-1","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"12","key":"12678_CR29","doi-asserted-by":"publisher","first-page":"e1007485","DOI":"10.1371\/journal.pcbi.1007485","volume":"15","author":"SM Konig","year":"2019","unstructured":"Konig SM, Rissler V, Terkelsen T, Lambrughi MPapaleo E (2019) Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level. PLoS Comput Biol 15(12):e1007485. https:\/\/doi.org\/10.1371\/journal.pcbi.1007485","journal-title":"PLoS Comput Biol"},{"issue":"7042","key":"12678_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677\u2013681. https:\/\/doi.org\/10.1038\/nature03579","journal-title":"Nature"},{"issue":"6","key":"12678_CR31","doi-asserted-by":"publisher","first-page":"107375","DOI":"10.1016\/j.jbc.2024.107375","volume":"300","author":"L Duan","year":"2024","unstructured":"Duan L, Tadi MJ, O\u2019hara KMMaki CG (2024) Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem 300(6):107375. https:\/\/doi.org\/10.1016\/j.jbc.2024.107375","journal-title":"J Biol Chem"},{"issue":"2","key":"12678_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41419-017-0169-2","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Liu L, Chang H, Zou ZXing D (2018) Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer. Cell Death Dis 9(2):137. https:\/\/doi.org\/10.1038\/s41419-017-0169-2","journal-title":"Cell Death Dis"},{"issue":"2","key":"12678_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2013.06.007","volume":"51","author":"CE Foulds","year":"2013","unstructured":"Foulds CE, Feng Q, Ding C, Bailey S, Hunsaker TL, Malovannaya A et al (2013) Proteomic analysis of coregulators bound to ERalpha on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 51(2):185\u2013199. https:\/\/doi.org\/10.1016\/j.molcel.2013.06.007","journal-title":"Mol Cell"},{"issue":"17\u201318","key":"12678_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1101\/gad.316646.118","volume":"32","author":"R Siersbaek","year":"2018","unstructured":"Siersbaek R, Kumar SCarroll JS (2018) Signaling pathways and steroid receptors modulating estrogen receptor alpha function in breast cancer. Genes Dev 32(17\u201318):1141\u20131154. https:\/\/doi.org\/10.1101\/gad.316646.118","journal-title":"Genes Dev"},{"issue":"3","key":"12678_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/0008-5472.CAN-12-2418","volume":"73","author":"T Dalotto-Moreno","year":"2013","unstructured":"Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP et al (2013) Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73(3):1107\u20131117. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2418","journal-title":"Cancer Res"},{"key":"12678_CR36","doi-asserted-by":"publisher","first-page":"1194835","DOI":"10.3389\/fonc.2023.1194835","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Wang C, Huang T, Yu XTian B (2023) The role of cancer-associated fibroblasts in breast cancer metastasis. Front Oncol 13:1194835. https:\/\/doi.org\/10.3389\/fonc.2023.1194835","journal-title":"Front Oncol"},{"issue":"1","key":"12678_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1756-9966-28-67","volume":"28","author":"MZ Gilcrease","year":"2009","unstructured":"Gilcrease MZ, Zhou X, Lu X, Woodward WA, Hall BEMorrissey PJ (2009) Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res 28(1):67. https:\/\/doi.org\/10.1186\/1756-9966-28-67","journal-title":"J Exp Clin Cancer Res"},{"key":"12678_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.canlet.2018.10.015","volume":"442","author":"S Wen","year":"2019","unstructured":"Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M et al (2019) Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling. Cancer Lett 442:320\u2013332. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.015","journal-title":"Cancer Lett"},{"issue":"1","key":"12678_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"X Zhang YWang","year":"2020","unstructured":"Zhang YWang X (2020) Targeting the Wnt\/beta-catenin signaling pathway in cancer. J Hematol Oncol 13(1):165. https:\/\/doi.org\/10.1186\/s13045-020-00990-3","journal-title":"J Hematol Oncol"},{"issue":"11","key":"12678_CR40","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s41594-018-0147-0","volume":"25","author":"J O\u2019reilly FJRappsilber","year":"2018","unstructured":"O\u2019reilly FJRappsilber J (2018) Cross-linking mass spectrometry: methods and applications in structural, molecular and systems biology. Nat Struct Mol Biol 25(11):1000\u20131008. https:\/\/doi.org\/10.1038\/s41594-018-0147-0","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"12678_CR41","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1038\/s41467-024-52699-3","volume":"15","author":"OR Dunce JMDavies","year":"2024","unstructured":"Dunce JMDavies OR (2024) BRCA2 stabilises RAD51 and DMC1 nucleoprotein filaments through a conserved interaction mode. Nat Commun 15(1):8292. https:\/\/doi.org\/10.1038\/s41467-024-52699-3","journal-title":"Nat Commun"},{"issue":"1","key":"12678_CR42","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1038\/s41467-022-31809-z","volume":"13","author":"PC Havugimana","year":"2022","unstructured":"Havugimana PC, Goel RK, Phanse S, Youssef A, Padhorny D, Kotelnikov S et al (2022) Scalable multiplex co-fractionation\/mass spectrometry platform for accelerated protein interactome discovery. Nat Commun 13(1):4043. https:\/\/doi.org\/10.1038\/s41467-022-31809-z","journal-title":"Nat Commun"},{"issue":"1","key":"12678_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11307-021-01639-4","volume":"24","author":"J Yang","year":"2022","unstructured":"Yang J, Davis T, Kazerouni AS, Chen YI, Bloom MJ, Yeh HC et al (2022) Longitudinal FRET Imaging of Glucose and Lactate Dynamics and Response to Therapy in Breast Cancer Cells. Mol Imaging Biol 24(1):144\u2013155. https:\/\/doi.org\/10.1007\/s11307-021-01639-4","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"12678_CR44","doi-asserted-by":"publisher","first-page":"e92737","DOI":"10.1371\/journal.pone.0092737","volume":"9","author":"MS Kuo","year":"2014","unstructured":"Kuo MS, Auriau J, Pierre-Eugene CIssad T (2014) Development of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensor. PLoS ONE 9(3):e92737. https:\/\/doi.org\/10.1371\/journal.pone.0092737","journal-title":"PLoS ONE"},{"issue":"3","key":"12678_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jmcb\/mjv064","volume":"8","author":"XL Mo","year":"2016","unstructured":"Mo XL, Luo Y, Ivanov AA, Su R, Havel JJ, Li Z et al (2016) Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. J Mol Cell Biol 8(3):271\u2013281. https:\/\/doi.org\/10.1093\/jmcb\/mjv064","journal-title":"J Mol Cell Biol"},{"issue":"D1","key":"12678_CR46","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R et al (2023) The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51(D1):D638\u2013D646. https:\/\/doi.org\/10.1093\/nar\/gkac1000","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"12678_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.3978","volume":"30","author":"R Oughtred","year":"2021","unstructured":"Oughtred R, Rust J, Chang C, Breitkreutz BJ, Stark C, Willems A et al (2021) The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci 30(1):187\u2013200. https:\/\/doi.org\/10.1002\/pro.3978","journal-title":"Protein Sci"},{"issue":"W1","key":"12678_CR48","doi-asserted-by":"publisher","first-page":"W283","DOI":"10.1093\/nar\/gkaf423","volume":"53","author":"YJ Kang","year":"2025","unstructured":"Kang YJ, Pan L, Liu Y, Rong Z, Liu JLiu F (2025) GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research. Nucleic Acids Res 53(W1):W283\u2013W290. https:\/\/doi.org\/10.1093\/nar\/gkaf423","journal-title":"Nucleic Acids Res"},{"issue":"8016","key":"12678_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A et al (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630(8016):493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","journal-title":"Nature"},{"issue":"5","key":"12678_CR50","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1109\/TCBB.2023.3262119","volume":"20","author":"I Berber","year":"2023","unstructured":"Berber I, Erten CKazan H (2023) Predator: Predicting the Impact of Cancer Somatic Mutations on Protein-Protein Interactions. IEEE\/ACM Trans Comput Biol Bioinform 20(5):3163\u20133172. https:\/\/doi.org\/10.1109\/TCBB.2023.3262119","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"issue":"269","key":"12678_CR51","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci Signal"},{"issue":"2","key":"12678_CR52","doi-asserted-by":"publisher","first-page":"103916","DOI":"10.1016\/j.sjbs.2023.103916","volume":"31","author":"S Sofi","year":"2024","unstructured":"Sofi S, Mehraj U, Jan N, Almilaibary A, Ahmad I, Ahmad F et al (2024) Clinicopathological Significance and Expression Pattern of Bcl2 in Breast Cancer: A Comprehensive in silico and in vitro Study. Saudi J Biol Sci 31(2):103916. https:\/\/doi.org\/10.1016\/j.sjbs.2023.103916","journal-title":"Saudi J Biol Sci"},{"key":"12678_CR53","doi-asserted-by":"publisher","unstructured":"Foutadakis S, Kordias D, Vatsellas GMagklara A (2024) Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast Cancer by Single-Cell Transcriptomic Analysis. Int J Mol Sci 25(13). https:\/\/doi.org\/10.3390\/ijms25136853","DOI":"10.3390\/ijms25136853"},{"key":"12678_CR54","doi-asserted-by":"publisher","first-page":"1148861","DOI":"10.3389\/fonc.2023.1148861","volume":"13","author":"E Ochoa SHernandez-Lemus","year":"2023","unstructured":"Ochoa SHernandez-Lemus E (2023) Molecular mechanisms of multi-omic regulation in breast cancer. Front Oncol 13:1148861. https:\/\/doi.org\/10.3389\/fonc.2023.1148861","journal-title":"Front Oncol"},{"key":"12678_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.47176\/mjiri.38.63","volume":"38","author":"Z Hosseinpour","year":"2024","unstructured":"Hosseinpour Z, Rezaei Tavirani MEsmaeil Akbari M (2024) Integrated Analysis of Multi-Omic Data Reveals Regulatory Mechanisms and Network Characteristics in Breast Cancer. Med J Islam Repub Iran 38:63. https:\/\/doi.org\/10.47176\/mjiri.38.63","journal-title":"Med J Islam Repub Iran"},{"issue":"9","key":"12678_CR56","doi-asserted-by":"publisher","first-page":"e9443","DOI":"10.15252\/msb.20209443","volume":"16","author":"A Shenoy","year":"2020","unstructured":"Shenoy A, Belugali Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I et al (2020) Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Mol Syst Biol 16(9):e9443. https:\/\/doi.org\/10.15252\/msb.20209443","journal-title":"Mol Syst Biol"},{"issue":"5","key":"12678_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y et al (2022) Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res 32(5):477\u2013490. https:\/\/doi.org\/10.1038\/s41422-022-00614-0","journal-title":"Cell Res"},{"issue":"11","key":"12678_CR58","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.cell.2022.04.014","volume":"185","author":"X Mo","year":"2022","unstructured":"Mo X, Niu Q, Ivanov AA, Tsang YH, Tang C, Shu C et al (2022) Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell 185(11):1974\u20131985 e1912. https:\/\/doi.org\/10.1016\/j.cell.2022.04.014","journal-title":"Cell"},{"key":"12678_CR59","doi-asserted-by":"publisher","first-page":"116324","DOI":"10.1016\/j.bmc.2021.116324","volume":"45","author":"X Yang","year":"2021","unstructured":"Yang X, Fan D, Troha AH, Ahn HM, Qian K, Liang B et al (2021) Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorg Med Chem 45:116324. https:\/\/doi.org\/10.1016\/j.bmc.2021.116324","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"12678_CR60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13058-024-01926-2","volume":"26","author":"J Foo","year":"2024","unstructured":"Foo J, Gentile F, Massah S, Morin H, Singh K, Lee J et al (2024) Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2). Breast Cancer Res 26(1):168. https:\/\/doi.org\/10.1186\/s13058-024-01926-2","journal-title":"Breast Cancer Res"},{"key":"12678_CR61","doi-asserted-by":"publisher","first-page":"116114","DOI":"10.1016\/j.ejmech.2023.116114","volume":"265","author":"SH Myers","year":"2024","unstructured":"Myers SH, Poppi L, Rinaldi F, Veronesi M, Ciamarone A, Previtali V et al (2024) An (19)F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer. Eur J Med Chem 265:116114. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116114","journal-title":"Eur J Med Chem"},{"issue":"2","key":"12678_CR62","doi-asserted-by":"publisher","first-page":"12431","DOI":"10.1080\/21655979.2021.2005747","volume":"12","author":"N Wang","year":"2021","unstructured":"Wang N, Zhang H, Li D, Jiang C, Zhao HTeng Y (2021) Identification of novel biomarkers in breast cancer via integrated bioinformatics analysis and experimental validation. Bioengineered 12(2):12431\u201312446. https:\/\/doi.org\/10.1080\/21655979.2021.2005747","journal-title":"Bioengineered"},{"issue":"3","key":"12678_CR63","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/mmr.2017.6101","volume":"15","author":"C Peng","year":"2017","unstructured":"Peng C, Ma W, Xia WZheng W (2017) Integrated analysis of differentially expressed genes and pathways in triple\u2013negative breast cancer. Mol Med Rep 15(3):1087\u20131094. https:\/\/doi.org\/10.3892\/mmr.2017.6101","journal-title":"Mol Med Rep"},{"issue":"11","key":"12678_CR64","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1093\/annonc\/mdt277","volume":"24","author":"TM Abdel-Fatah","year":"2013","unstructured":"Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S et al (2013) Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol 24(11):2801\u20132807. https:\/\/doi.org\/10.1093\/annonc\/mdt277","journal-title":"Ann Oncol"},{"issue":"14","key":"12678_CR65","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/15384101.2022.2054096","volume":"21","author":"KJ Winder MLCampbell","year":"2022","unstructured":"Winder MLCampbell KJ (2022) MCL-1 is a clinically targetable vulnerability in breast cancer. Cell Cycle 21(14):1439\u20131455. https:\/\/doi.org\/10.1080\/15384101.2022.2054096","journal-title":"Cell Cycle"},{"issue":"13","key":"12678_CR66","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AHHuang DCS (2021) BCL2 and MCL1 inhibitors for hematologic malignancies. Blood 138(13):1120\u20131136. https:\/\/doi.org\/10.1182\/blood.2020006785","journal-title":"Blood"},{"issue":"6","key":"12678_CR67","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","volume":"25","author":"I Ploumaki","year":"2023","unstructured":"Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I et al (2023) Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clin Transl Oncol 25(6):1554\u20131578. https:\/\/doi.org\/10.1007\/s12094-022-03070-9","journal-title":"Clin Transl Oncol"},{"issue":"5689","key":"12678_CR68","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1126\/science.1099191","volume":"305","author":"LD Walensky","year":"2004","unstructured":"Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305(5689):1466\u20131470. https:\/\/doi.org\/10.1126\/science.1099191","journal-title":"Science"},{"issue":"6","key":"12678_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"1","key":"12678_CR70","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-pathmechdis-031521-033231","volume":"20","author":"J Cierpicki TGrembecka","year":"2025","unstructured":"Cierpicki TGrembecka J (2025) Targeting Protein-Protein Interactions in Hematologic Malignancies. Annu Rev Pathol 20(1):275\u2013301. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-033231","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"12678_CR71","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E et al (2020) Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest 130(2):981\u2013997. https:\/\/doi.org\/10.1172\/JCI129126","journal-title":"J Clin Invest"},{"key":"12678_CR72","doi-asserted-by":"publisher","unstructured":"Brzezinka K, Nevedomskaya E, Lesche R, Haegebarth A, Ter Laak A, Fernandez-Montalvan AE et al (2020) Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target. Cancers (Basel) 12(1). https:\/\/doi.org\/10.3390\/cancers12010201","DOI":"10.3390\/cancers12010201"},{"issue":"25","key":"12678_CR73","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/blood.2020006575","volume":"136","author":"H Miao","year":"2020","unstructured":"Miao H, Kim E, Chen D, Purohit T, Kempinska K, Ropa J et al (2020) Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood 136(25):2958\u20132963. https:\/\/doi.org\/10.1182\/blood.2020006575","journal-title":"Blood"},{"issue":"1","key":"12678_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","volume":"184","author":"SL Schreiber","year":"2021","unstructured":"Schreiber SL (2021) The Rise of Molecular Glues. Cell 184(1):3\u20139. https:\/\/doi.org\/10.1016\/j.cell.2020.12.020","journal-title":"Cell"},{"issue":"9","key":"12678_CR75","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai X, Gan W, Li X, Wang S, Zhang W, Huang L et al (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23(9):1063\u20131071. https:\/\/doi.org\/10.1038\/nm.4378","journal-title":"Nat Med"},{"issue":"1","key":"12678_CR76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","volume":"9","author":"H Nada","year":"2024","unstructured":"Nada H, Choi Y, Kim S, Jeong KS, Meanwell NALee K (2024) New insights into protein-protein interaction modulators in drug discovery and therapeutic advance. Signal Transduct Target Ther 9(1):341. https:\/\/doi.org\/10.1038\/s41392-024-02036-3","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"12678_CR77","doi-asserted-by":"publisher","first-page":"11516","DOI":"10.1021\/acs.jmedchem.5c00425","volume":"68","author":"J Liang","year":"2025","unstructured":"Liang J, Wang D, Wu Y, Shi J, Xie B, Xiao R et al (2025) Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer. J Med Chem 68(11):11516\u201311542. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00425","journal-title":"J Med Chem"},{"issue":"6","key":"12678_CR78","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","volume":"15","author":"MA Maneiro","year":"2020","unstructured":"Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR et al (2020) Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chem Biol 15(6):1306\u20131312. https:\/\/doi.org\/10.1021\/acschembio.0c00285","journal-title":"ACS Chem Biol"},{"key":"12678_CR79","doi-asserted-by":"publisher","first-page":"1226289","DOI":"10.3389\/fonc.2023.1226289","volume":"13","author":"SI Tantawy","year":"2023","unstructured":"Tantawy SI, Timofeeva N, Sarkar AGandhi V (2023) Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol 13:1226289. https:\/\/doi.org\/10.3389\/fonc.2023.1226289","journal-title":"Front Oncol"},{"key":"12678_CR80","doi-asserted-by":"publisher","first-page":"102073","DOI":"10.1016\/j.tranon.2024.102073","volume":"49","author":"NT Conlon","year":"2024","unstructured":"Conlon NT, Roche S, Mahdi AF, Browne A, Breen L, Gaubatz J et al (2024) Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo. Transl Oncol 49:102073. https:\/\/doi.org\/10.1016\/j.tranon.2024.102073","journal-title":"Transl Oncol"},{"issue":"3","key":"12678_CR81","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER et al (2019) Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov 9(3):342\u2013353. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1119","journal-title":"Cancer Discov"},{"issue":"1","key":"12678_CR82","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","volume":"10","author":"RW Birkinshaw","year":"2019","unstructured":"Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA et al (2019) Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun 10(1):2385. https:\/\/doi.org\/10.1038\/s41467-019-10363-1","journal-title":"Nat Commun"},{"issue":"4","key":"12678_CR83","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A et al (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369\u2013384e313. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.005","journal-title":"Cancer Cell"},{"issue":"1","key":"12678_CR84","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","volume":"17","author":"M Hinz NJucker","year":"2019","unstructured":"Hinz NJucker M (2019) Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal 17(1):154. https:\/\/doi.org\/10.1186\/s12964-019-0450-3","journal-title":"Cell Commun Signal"},{"issue":"5","key":"12678_CR85","doi-asserted-by":"publisher","first-page":"e24077","DOI":"10.4161\/onci.24077","volume":"2","author":"M Salatino","year":"2013","unstructured":"Salatino M, Dalotto-Moreno TRabinovich GA (2013) Thwarting galectin-induced immunosuppression in breast cancer. Oncoimmunology 2(5):e24077. https:\/\/doi.org\/10.4161\/onci.24077","journal-title":"Oncoimmunology"},{"issue":"20","key":"12678_CR86","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS et al (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"1","key":"12678_CR87","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41467-021-22913-7","volume":"12","author":"F Tian","year":"2021","unstructured":"Tian F, Zhang S, Liu C, Han Z, Liu Y, Deng J et al (2021) Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun 12(1):2536. https:\/\/doi.org\/10.1038\/s41467-021-22913-7","journal-title":"Nat Commun"},{"issue":"1","key":"12678_CR88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-022-28524-0","volume":"13","author":"K Asleh","year":"2022","unstructured":"Asleh K, Negri GL, Spencer Miko SE, Colborne S, Hughes CS, Wang XQ et al (2022) Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat Commun 13(1):896. https:\/\/doi.org\/10.1038\/s41467-022-28524-0","journal-title":"Nat Commun"},{"issue":"23","key":"12678_CR89","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1016\/j.cell.2024.10.038","volume":"187","author":"JF Greenblatt","year":"2024","unstructured":"Greenblatt JF, Alberts BMKrogan NJ (2024) Discovery and significance of protein-protein interactions in health and disease. Cell 187(23):6501\u20136517. https:\/\/doi.org\/10.1016\/j.cell.2024.10.038","journal-title":"Cell"},{"key":"12678_CR90","doi-asserted-by":"publisher","unstructured":"Wu YJiang T (2022) Developments in FRET- and BRET-Based Biosensors. Micromachines (Basel) 13(10). https:\/\/doi.org\/10.3390\/mi13101789","DOI":"10.3390\/mi13101789"},{"key":"12678_CR91","doi-asserted-by":"publisher","first-page":"1739303","DOI":"10.3389\/frai.2026.1739303","volume":"9","author":"C Chakraborty","year":"2026","unstructured":"Chakraborty C, Bhattacharya MLee SS (2026) The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology. Front Artif Intell 9:1739303. https:\/\/doi.org\/10.3389\/frai.2026.1739303","journal-title":"Front Artif Intell"},{"issue":"1","key":"12678_CR92","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s42003-020-1042-x","volume":"3","author":"P Savage","year":"2020","unstructured":"Savage P, Pacis A, Kuasne H, Liu L, Lai D, Wan A et al (2020) Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Commun Biol 3(1):310. https:\/\/doi.org\/10.1038\/s42003-020-1042-x","journal-title":"Commun Biol"},{"issue":"10","key":"12678_CR93","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1016\/j.apsb.2023.05.035","volume":"13","author":"D Wu","year":"2023","unstructured":"Wu D, Li Y, Zheng L, Xiao H, Ouyang L, Wang G et al (2023) Small molecules targeting protein-protein interactions for cancer therapy. Acta Pharm Sin B 13(10):4060\u20134088. https:\/\/doi.org\/10.1016\/j.apsb.2023.05.035","journal-title":"Acta Pharm Sin B"},{"key":"12678_CR94","doi-asserted-by":"publisher","unstructured":"Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G et al (2017) Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med 9(401). https:\/\/doi.org\/10.1126\/scitranslmed.aam7049","DOI":"10.1126\/scitranslmed.aam7049"},{"key":"12678_CR95","doi-asserted-by":"publisher","unstructured":"Aouad P, Halabi K, Hayar B, Sflomos G, Brisken C, Metcalfe C et al (2026) Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance. NPJ Breast Cancer 12(1). https:\/\/doi.org\/10.1038\/s41523-026-00928-x","DOI":"10.1038\/s41523-026-00928-x"},{"key":"12678_CR96","doi-asserted-by":"publisher","unstructured":"El-Tanani M, Rabbani SA, Wali AF, El-Tanani YSharma S (2026) Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology. Biology (Basel) 15(10). https:\/\/doi.org\/10.3390\/biology15100759","DOI":"10.3390\/biology15100759"},{"issue":"11","key":"12678_CR97","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/s12276-020-00528-0","volume":"52","author":"I Cha JLee","year":"2020","unstructured":"Cha JLee I (2020) Single-cell network biology for resolving cellular heterogeneity in human diseases. Exp Mol Med 52(11):1798\u20131808. https:\/\/doi.org\/10.1038\/s12276-020-00528-0","journal-title":"Exp Mol Med"},{"key":"12678_CR98","doi-asserted-by":"publisher","unstructured":"Yang X, Cui W, Wang LZheng Y (2026) A Brief Progress in Methods for Deciphering Protein-Protein Interaction Networks. Int J Mol Sci 27(4). https:\/\/doi.org\/10.3390\/ijms27041844","DOI":"10.3390\/ijms27041844"},{"issue":"1","key":"12678_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41389-024-00521-6","volume":"13","author":"A Sharma","year":"2024","unstructured":"Sharma A, Debik J, Naume B, Ohnstad HO, Oslo Breast Cancer C, Bathen TF et al (2024) Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes. Oncogenesis 13(1):22. https:\/\/doi.org\/10.1038\/s41389-024-00521-6","journal-title":"Oncogenesis"},{"key":"12678_CR100","doi-asserted-by":"publisher","unstructured":"Tancredi R, Sobhani N, Catalano M, Roviello GGenerali D (2025) Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies. Genes (Basel) 16(4). https:\/\/doi.org\/10.3390\/genes16040443","DOI":"10.3390\/genes16040443"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12678-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:16:59Z","timestamp":1788355019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12678-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12678"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12678-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All schematic figures, protein interaction network diagrams and experimental schematic graphs contained in this manuscript were fully hand-drawn and finalized with Adobe Illustrator CS6. At the early manuscript preparation stage, generative AI tools were only applied for two auxiliary tasks: generating a preliminary rough layout sketch of the figure panels for reference, and grammatical revision & typo correction of the full-text English manuscript. Not any core graphical components including molecular structures, protein icons, cell models, pathway connection arrows, label layouts and figure formatting were directly produced by generative AI in the final submitted figures. All complete final figures were manually redrawn, revised and optimized from the initial AI draft layout. All molecular annotations, signalling pathway logic, interaction relationships, figure legends and uniform formatting specifications were double-checked, validated and proofread by all authors to ensure complete accuracy and standardization.","order":4,"name":"Ethics","label":"Generative AI Usage and Figure Preparation Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1511"}}